A new study from the University of Oklahoma suggests that small genetic differences in two proteins – previously known for their role in premature infants’ lungs – may also influence how their eyes develop, potentially affecting the risk of retinopathy of prematurity (ROP).
The success of GLP-1 medications for treating Type 2 diabetes and obesity naturally leads to a related question: Do GLP-1 drugs affect cancer risk, which is often associated with obesity and Type 2 diabetes?
The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer Center. The treatment offers potential hope for patients whose tumors lack a key DNA repair protein called ATM.
Abdul Rafeh Naqash, M.D., associate professor at the University of Oklahoma College of Medicine and an oncologist at OU Health Stephenson Cancer Center, has been named a fellow of the American Society of Clinical Oncology (FASCO).
OKLAHOMA CITY – More than 800 people attended the 2025 Connect+Cure Gala on Wednesday night, raising $4.7 million to support research and programs at the University of Oklahoma Health Harold Hamm Diabetes Center.